Versus hydroxychloroquine (DrugBank: Hydroxychloroquine)
23 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
34 | Neurofibromatosis | 0 |
41 | Giant cell arteritis | 0 |
43 | Microscopic polyangiitis | 0 |
44 | Wegener granulomatosis | 0 |
45 | Eosinophilic granulomatosis with Polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
48 | Primary antiphospholipid syndrome | 0 |
49 | Systemic lupus erythematosus | 1 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
66 | IgA nephropathy | 0 |
84 | Sarcoidosis | 0 |
89 | Lymphangioleiomyomatosis | 0 |
90 | Retinitis pigmentosa | 0 |
96 | Crohn disease | 0 |
218 | Alport syndrome | 0 |
222 | Primary nephrotic syndrome | 0 |
234 | Peroxisomal disease (except Adrenoleukodystrophy) | 0 |
254 | Porphyria | 0 |
271 | Ankylosing spondylitis | 0 |
298 | Hereditary pancreatitis | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00413361 (ClinicalTrials.gov) | June 2007 | 18/12/2006 | The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS | Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study | Systemic Lupus Erythematosus | Drug: versus hydroxychloroquine | Assistance Publique - Hôpitaux de Paris | Sanofi-Synthelabo | Completed | 18 Years | N/A | Both | 543 | Phase 4 | France |